Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
27 July 2018Website:
http://www.adialpharma.comNext earnings report:
14 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | 18 min agoDividend
Analysts recommendations
Institutional Ownership
ADIL Latest News
Glen Allen, VA, October 23, 2024 – PRISM MediaWire – Adial Pharmaceuticals, Inc.
GLEN ALLEN, Va., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York.
GLEN ALLEN, Va., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced database lock for the pharmacokinetics study of AD04, the Company's lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients (defined as < 10 drinks/drinking day).
GLEN ALLEN, Va., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the second quarter of 2024.
Adial Pharmaceuticals (NASDAQ:ADIL) stock is rocketing higher on Tuesday after the clinical-stage biopharmaceutical company announced an update on its AD04 study. Adial Pharmaceuticals notes that AD04 is progressing to a second cohort in its pharmacokinetics study.
Making millions through the stock market is only possible in a few ways. Investors need one of these three things: Massive sums of capital to begin with Decades of time and more modest sums of capital More modest sums of capital and a combination of risk and luck We will be talking about the latter today: seven stocks you can buy for $2 that can 10X by 2025.
GLEN ALLEN, Va., May 29, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in the Spring MicroCap Rodeo Conference that will be held on Thursday, June 6, 2024 in New York City.
Adial Pharmaceuticals Inc (NASDAQ: ADIL) saw a 60% increase in its stock today after announcing positive results for its alcohol disorder drug. The Virginia-based company, valued at $7.7 million, reported promising results for its AD04 drug in a clinical trial involving patients with Alcohol Use Disorder (AUD).
Adial Pharmaceuticals (NASDAQ: ADIL ) stock is on the rise today after receiving favorable results from a peer review of its Alcohol Use Disorder ( AUD ) treatment. The focus of this peer review was on the Phase 3 clinical trial outcomes for AD04.
Adial Pharmaceuticals, Inc. (ADIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What type of business is Adial Pharmaceuticals?
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
What sector is Adial Pharmaceuticals in?
Adial Pharmaceuticals is in the Healthcare sector
What industry is Adial Pharmaceuticals in?
Adial Pharmaceuticals is in the Biotechnology industry
What country is Adial Pharmaceuticals from?
Adial Pharmaceuticals is headquartered in United States
When did Adial Pharmaceuticals go public?
Adial Pharmaceuticals initial public offering (IPO) was on 27 July 2018
What is Adial Pharmaceuticals website?
https://www.adialpharma.com
Is Adial Pharmaceuticals in the S&P 500?
No, Adial Pharmaceuticals is not included in the S&P 500 index
Is Adial Pharmaceuticals in the NASDAQ 100?
No, Adial Pharmaceuticals is not included in the NASDAQ 100 index
Is Adial Pharmaceuticals in the Dow Jones?
No, Adial Pharmaceuticals is not included in the Dow Jones index
When was Adial Pharmaceuticals the previous earnings report?
No data
When does Adial Pharmaceuticals earnings report?
The next expected earnings date for Adial Pharmaceuticals is 14 November 2024